Stomach cancer is a type of cancer that begins when the cancer cells form in the inner lining of the stomach. Stomach cancer is also known as gastric cancer. Gastric cancer usually progresses slowly. Some of the early symptoms include indigestion, heartburn, slight nausea, loss of appetite, etc. But, as the stomach tumour grows there may be more serious symptoms such as stomach pain, vomiting, yellowish eyes or skin, blood in stool, constipation, swelling in stomach, weight loss, etc.
Treatment for gastric cancer basically depends upon the stage of cancer. There are number of types of treatment available such as surgery, targeted drugs, chemotherapy, etc. The factors that propel the growth of the global Stomach Cancer Market include innovations in treatment, growing number of cancer treatment centers, increasing research and development activities, and combination therapies.
In addition, growing prevalence of lymphoma, adenocarcinoma, gastrointestinal stromal tumours, carcinoid tumours, etc. are also driving the growth of the global Stomach Cancer Market. On the other hand, there are also factors that hamper the growth of the market such as high cost of therapy and lack of sufficient financial support from health insurance policies.
In addition, there are also other factors that restraint the growth of the market such as strict monitoring processes for approving complicated nature of radiation devices and also less availability of commercial drugs for the treatment of stomach cancer. The global Stomach Cancer Market is classified on the basis of treatment type, end use and geography.
On the basis of treatment type, global Gastric Cancer Market is classified as surgery, chemo therapy, adjuvant chemotherapy, targeted drugs therapy, and radiation therapy. The targeted drugs therapy segment is further sub classified as Sunitinib (Sutent), Trastuzumab (Herceptin) and Imatinib (Gleevec).
Among the treatment type, targeted therapy segment is projected to account a large share of the global Stomach Cancer Market over the forecast period. The major factor that attributes to the growth of targeted therapy is due to delivery of advanced techniques such as stem cell therapy, immunotherapy or enzyme therapy.
On the basis of end user, global Stomach Cancer Market is classified hospitals, clinics, specialized cancer treatment centers and ambulatory surgical centers. Among the end user, hospitals and specialized cancer treatment centers segments together account a maximum share of the global Stomach Cancer Market. On the basis of geography, the global Stomach Cancer Market is classified asNorth America, Latin America, Eastern Europe, Western Europe, and Asia Pacific excluding Japan, Japan and Middle East & Africa.
The North American region comprises the U.S., and Canada. Latin America comprises Mexico and Brazil. The Western European region comprises Germany, Italy, France, England, Spain, Nordic countries, Belgium, The Netherlands, and Luxembourg. The Eastern European region comprises Poland, and Russia. Asia Pacific region comprises China, India, ASEAN, and Australia & New Zealand. The Middle East and Africa region comprises GCC, South Africa, and North Africa.
In case of geographical region, Asia-Pacific followed by Latin America is the most important markets for Stomach Cancer Treatment Market due to the large patient pool in case of stomach cancer. Whereas, Gastric Cancer Treatment Market in regions such as North America and Africa are projected to witness slow growth owing to low occurrence rate of stomach cancer. Some of the prominent players that fuel the growth of the global Stomach Cancer Market include Eli Lilly and company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck KGaA, Novartis International AG and Otsuka Holdings Co. Ltd.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."